Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

NCT00612898 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

239

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

HIV Infections

Interventions

DRUG: apricitabine
DRUG: lamivudine

Sponsor

Avexa